Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | In Stock | |
5 mg | $722 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,520 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,500 | In Stock |
Description | BN-82451 2HCl is a dual inhibitor of COX-1 and COX-2 and can be used to study Huntington's chorea and Parkinson's disease. |
In vivo | 1 - 10 mg/kg oral doses of BN82451 reduced the severity of fully established AIMs in a dose-related manner in a rat model of PD. This antimotor dysfunction effect was achieved with subchronic administration of lower doses of BN82451 compared with acute single treatments.The improvement in AIMs was not due to a reduction in general locomotor activity in the dyskinetic rats.BN82451 treatment significantly reversed the overexpression of c-Fos, FosB, and Arc mRNAs, which have been associated with the dyskinetic effects of levodopa.The effect of BN82451 was not due to a reduction in general motor activity in the dyskinetic rats. [1];After subchronic administration of 5 mg/kg/day subcutaneously for 5 days, IRC concentrations in the brain of male cynomolgus monkeys (Macaca fascicularis) were higher (cortex: 20.87±6.92 μM) than in plasma (1.16±0.33 μM), with a ratio of 18.2±2.5; at 2.5, 5, and 10 mg/kg IRC-082451, IRC concentrations in the brain of male cynomolgus monkeys were higher than in plasma (1.16±0.33 μM), with a ratio of 18.2±2.5. Subcutaneous injection into Macaca fascicularis quantified L-DOPA-induced dyskinesia and showed no significant effect on spontaneous motor activity in all acute treatments tested. [3] |
Alias | BN-82451B 2HCl, BN 82451B 2HCl |
Molecular Weight | 391.4 |
Formula | C18H28Cl2N2OS |
Cas No. | 663172-95-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.